文献速递心律失常血脂与心血管预防

亚临床房颤基线发作频率与持续时间对卒中或系统性栓塞风险的影响:ARTESiA 试验见解

Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.
PubMed 文献 · Circulation · 2024-09-04

本研究为 ARTESiA 试验的回顾性队列分析,纳入 3986 例有完整基线亚临床房颤(SCAF)数据的患者,评估随机化前 6 个月内 SCAF 发作频率及最长发作持续时间与卒中或系统性栓塞风险的关系,并分析其对阿哌沙班疗效的影响。结果显示,基线 SCAF 频率和最长发作持续时间均与卒中或系统性栓塞风险无关,且未改变阿哌沙班的治疗效应。

要点

  • 基线 SCAF 发作频率较高与卒中或系统性栓塞风险增加无关。
  • 随机化前 6 个月内最长 SCAF 发作持续时间与卒中或系统性栓塞风险无关。
  • SCAF 频率和持续时间均未改变阿哌沙班对卒中或系统性栓塞的降低效应。

核心结论

  • 在 ARTESiA 试验中,基线 SCAF 频率和最长发作持续时间与卒中或系统性栓塞风险无关,且未改变阿哌沙班的疗效。

研究设计与样本

  • ARTESiA 试验的回顾性队列研究,纳入 3986 例有完整基线 SCAF 数据的患者。
  • 使用 Cox 回归调整 CHA2DS2-VASc 评分和治疗分配(阿哌沙班或阿司匹林)。

主要发现

  • 703 例(17.6%)在入组前 6 个月内无 ≥6 分钟的 SCAF 发作。
  • 3283 例(82.4%)有 ≥1 次 ≥6 分钟 SCAF 发作,其中 2542 例(77.4%)发作 ≤5 次,741 例(22.6%)发作 ≥6 次。
  • 最长发作持续时间 <1 小时者 1030 例(31.4%),1 至 <6 小时者 1421 例(43.3%),>6 小时者 832 例(25.3%)。
  • 较高基线 SCAF 频率与卒中或系统性栓塞风险增加无关:1-5 次发作 vs ≥6 次发作的调整风险比为 0.89(95% CI 0.59-1.34)。
  • 最长 SCAF 持续时间与卒中或系统性栓塞风险无关:1-6 小时 vs <1 小时的调整风险比为 1.27(95% CI 0.85-1.90);>6 小时 vs <1 小时的调整风险比为 1.02(95% CI 0.63-1.66)。

临床怎么用

  • 对于 device-detected SCAF 患者,基线发作频率和最长持续时间可能不应作为决定是否抗凝的主要依据。
  • 阿哌沙班降低卒中或系统性栓塞的效应不受 SCAF 频率或持续时间影响。

局限性

  • 本研究为回顾性队列分析,可能存在残余混杂。
  • SCAF 频率和持续时间基于随机化前 6 个月的监测数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population. METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA2DS2-VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect. RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted <1 hour in 1030 patients (31.4%), 1 to <6 hours in 1421 patients (43.3%), and >6 hours in 832 patients (25.3%). Higher baseline SCAF frequency was not associated with increased risk of stroke or systemic embolism: 1.1% for 1 to 5 episodes versus 1.2%/patient-year for ≥6 episodes (adjusted hazard ratio, 0.89 [95% CI, 0.59-1.34]). In an exploratory analysis, patients with previous SCAF but no episode ≥6 minutes in the 6 months before enrollment had a lower risk of stroke or systemic embolism than patients with at least one episode during that period (0.5% versus 1.1%/patient-year; adjusted hazard ratio, 0.48 [95% CI, 0.27-0.85]). The frequency of SCAF did not modify the reduction in stroke or systemic embolism with apixaban (Pinteraction=0.1). The duration of the longest SCAF episode in the 6 months before enrollment was not associated with the risk of stroke or systemic embolism during follow-up (<1 hour: 1.0%/patient-year [reference]; 1-6 hours: 1.2%/patient-year [adjusted hazard ratio, 1.27 (95% CI, 0.85-1.90)]; >6 hours: 1.0%/patient-year [adjusted hazard ratio, 1.02 (95% CI, 0.63-1.66)]). SCAF duration did not modify the reduction in stroke or systemic embolism with apixaban (Ptrend=0.1). CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01938248.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. McIntyre WF, Benz AP, Healey JS, et al. Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial. Circulation. 2024. PMID: 39229707. doi:10.1161/CIRCULATIONAHA.124.069903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。